Friday, July 10, 2026

Drug profile · INN

bifikafusp alfa

bifikafusp alfa (NIDLEGY) is an FDA-listed pharmaceutical active ingredient.

EMA: application withdrawn Antineoplastic and immunomodulating agents (L01) L01XY
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — bifikafusp alfa
Class
Antineoplastic and immunomodulating agents (L01)
Route
Patents
0
Programs
0
Data quality
0.83

Quick answer

bifikafusp alfa (NIDLEGY) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN bifikafusp alfa
Brand NIDLEGY
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XY

Approval history

Authority Status Date
EMA application withdrawn

Related & competitor drugs

  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. anagrelide Antineoplastic and immunomodulating agents (L01)
  3. apremilast Antineoplastic and immunomodulating agents (L04)
  4. arsenic trioxide Antineoplastic and immunomodulating agents (L01)
  5. axitinib Antineoplastic and immunomodulating agents (L01)
  6. azacitidine Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is bifikafusp alfa?

bifikafusp alfa (NIDLEGY) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for bifikafusp alfa?

NIDLEGY is a marketed brand name for bifikafusp alfa. Check FDA Drugs@FDA for the current US label holder and prescribing information.